TRCT
ALDX icon

Tower Research Capital (TRC)’s Aldeyra Therapeutics ALDX Stock Holding History

Tower Research Capital (TRC)’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$19.1K Buy
11,325
+6,320
+126% +$27.7K ﹤0.01% 3510
2025
Q4 		$25.9K Buy
5,005
+1,383
+38% +$7.11K ﹤0.01% 2906
2025
Q3 		$18.9K Sell
3,622
-3,891
-52% -$20.3K ﹤0.01% 3361
2025
Q2 		$28.8K Buy
7,513
+5,314
+242% +$13.7K ﹤0.01% 3437
2025
Q1 		$12.6K Sell
2,199
-2,227
-50% -$13.2K ﹤0.01% 3432
2024
Q4 		$22.1K Buy
4,426
+1,122
+34% +$5.76K ﹤0.01% 3111
2024
Q3 		$17.8K Sell
3,304
-6,325
-66% -$30.1K ﹤0.01% 3296
2024
Q2 		$31.9K Buy
9,629
+9,136
+1,853% +$35.8K ﹤0.01% 3439
2024
Q1 		$1.61K Sell
493
-21,674
-98% -$71.3K ﹤0.01% 5233
2023
Q4 		$77.8K Buy
22,167
+20,264
+1,065% +$62.5K ﹤0.01% 2830
2023
Q3 		$12.7K Sell
1,903
-2,414
-56% -$17.9K ﹤0.01% 3871
2023
Q2 		$36.2K Buy
4,317
+4,308
+47,867% +$42.4K ﹤0.01% 2861
2023
Q1 		$0 Buy
+9
New +$64 ﹤0.01% 5764
2022
Q4 		– Sell
-6,754
Closed -$36K – 5845
2022
Q3 		$36K Buy
+6,754
New +$40.5K ﹤0.01% 3447
2022
Q2 		– Sell
-18,990
Closed -$85K – 6048
2022
Q1 		$85K Buy
18,990
+7,147
+60% +$28.5K ﹤0.01% 2330
2021
Q4 		$47K Sell
11,843
-8,168
-41% -$62.3K ﹤0.01% 2800
2021
Q3 		$175K Buy
20,011
+17,612
+734% +$162K ﹤0.01% 1936
2021
Q2 		$27K Buy
2,399
+873
+57% +$10.5K ﹤0.01% 3590
2021
Q1 		$18K Sell
1,526
-857
-36% -$9.87K ﹤0.01% 3951
2020
Q4 		$16K Buy
2,383
+574
+32% +$4.03K ﹤0.01% 3995
2020
Q3 		$13K Sell
1,809
-625
-26% -$4.04K ﹤0.01% 3984
2020
Q2 		$10K Buy
+2,434
New +$8.89K ﹤0.01% 3995
2020
Q1 		– Sell
-6,981
Closed -$41K – 2985
2019
Q4 		$41K Buy
6,981
+4,688
+204% +$27.1K ﹤0.01% 1456
2019
Q3 		$12K Buy
2,293
+2,094
+1,052% +$11.3K ﹤0.01% 2803
2019
Q2 		$1K Buy
+199
New +$1.5K ﹤0.01% 3398
2019
Q1 		– Sell
-2,141
Closed -$18K – 3740
2018
Q4 		$18K Buy
2,141
+1,783
+498% +$18.3K ﹤0.01% 2005
2018
Q3 		$5K Sell
358
-1,633
-82% -$13.2K ﹤0.01% 3093
2018
Q2 		$15K Buy
1,991
+938
+89% +$7.48K ﹤0.01% 2575
2018
Q1 		$8K Buy
1,053
+1,029
+4,288% +$7.81K ﹤0.01% 2528
2017
Q4 		$0 Sell
24
-3,159
-99% -$20.8K ﹤0.01% 3463
2017
Q3 		$23K Buy
3,183
+3,171
+26,425% +$16.6K ﹤0.01% 2636
2017
Q2 		$0 Sell
12
-348
-97% -$1.6K ﹤0.01% 2642
2017
Q1 		$2K Sell
360
-3,400
-90% -$17.5K ﹤0.01% 2580
2016
Q4 		$20K Buy
3,760
+3,181
+549% +$18.7K ﹤0.01% 2122
2016
Q3 		$5K Buy
+579
New +$3.54K ﹤0.01% 2519
2016
Q2 		– Sell
-636
Closed -$3K – 4383
2016
Q1 		$3K Buy
636
+480
+308% +$2.31K ﹤0.01% 3039
2015
Q4 		$1K Sell
156
-1,149
-88% -$7.72K ﹤0.01% 4005
2015
Q3 		$8K Buy
1,305
+1,085
+493% +$8.47K ﹤0.01% 2450
2015
Q2 		$2K Sell
220
-1,024
-82% -$8.83K ﹤0.01% 3685
2015
Q1 		$13K Buy
+1,244
New +$12.7K ﹤0.01% 2570
2014
Q4 		– Sell
-414
Closed -$2K – 3962
2014
Q3 		$2K Sell
414
-365
-47% -$1.78K ﹤0.01% 3762
2014
Q2 		$5K Buy
+779
New +$5.23K ﹤0.01% 2825

Other funds holding ALDX

KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Tower Research Capital (TRC)'s ALDX Position: Q1 2026 in Review

Tower Research Capital (TRC) increased its Aldeyra Therapeutics (ALDX) stake by 126% in Q1 2026, buying an estimated $27.7K and bringing the position to 11,325 shares worth $19.1K. The position accounts for ﹤0.01% of the portfolio, ranked #3510.

Tower Research Capital (TRC) first reported a position in ALDX in Q2 2014 and has held it in 42 quarters since. The position peaked at $175K in Q3 2021. 126 funds tracked by Wall St. Rank hold ALDX as of Q1 2026.

  • Tower Research Capital (TRC) held 11,325 shares of Aldeyra Therapeutics worth $19.1K as of Q1 2026.
  • Tower Research Capital (TRC) bought 6,320 Aldeyra Therapeutics shares in Q1 2026, an estimated $27.7K.
  • Aldeyra Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #3510 holding.
  • Tower Research Capital (TRC) first reported a position in Aldeyra Therapeutics in Q2 2014 and has held it in 42 quarters since.
  • Tower Research Capital (TRC)'s Aldeyra Therapeutics position peaked at $175K in Q3 2021.
  • 126 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.